ALT vs ASMB

ALT exhibits severe financial distress despite strong revenue growth, as evidenced by a Piotroski F-Score of 1/9—indicating poor operational and financial health. The Altman Z-Score is unavailable, but the company's negative profitability metrics (ROE: -50.57%, ROA: -28.17%), massive operating losses, and negative earnings suggest high distress risk. While revenue growth is explosive at 420% YoY, this is not translating into profitability or cash flow, and the stock trades at an extreme Price/Sales of 10,690.50, reflecting speculative valuation. Analysts recommend 'buy' with a $17.22 target, but this is likely driven by pipeline optimism rather than fundamentals. The technical trend is bearish, and insider activity is neutral, offering no conviction.

ASMB's Advanced Deterministic Scorecard reveals severe financial health concerns: a Piotroski F-Score of 0/9 indicates extreme operational weakness, and the absence of an Altman Z-Score raises distress risk concerns. Despite this, the company exhibits strong revenue growth (57.6% YoY) and improving earnings surprises in recent quarters, suggesting potential operational turnaround. However, negative profitability metrics—such as a -103.65% profit margin and negative ROE—highlight persistent losses. The stock trades at a premium valuation (Price/Sales of 11.96) with no dividend, reflecting high growth expectations rather than intrinsic value. Analysts maintain a target price of $47.75, implying upside, but consensus is weak with only four analysts.